SOFW SOFWAVE MEDICAL LTD

Dr. Kavita Darji Wins the Drs. Alastair and Jean D. Carruthers Award at ASDS 2024 for Sofwave SUPERB™ Abstract

Dr. Kavita Darji Wins the Drs. Alastair and Jean D. Carruthers Award at ASDS 2024 for Sofwave SUPERB™ Abstract

Abstract entitled, “Safety and Efficacy of Synchronous Ultrasound Parallel Beam Technology to Lift the Upper Lip and Improve Perioral Rhytids” selected as the highest rated Cosmetic Dermatologic Surgery Fellow Research Abstract

SAN CLEMENTE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced Kavita Darji, MD, FAAD, board-certified dermatologist and cosmetic dermatologic surgeon who completed her ASDS-accredited cosmetic dermatologic surgery fellowship, was selected as the winner of the . The award is given to the highest rated Cosmetic Dermatologic Surgery Fellow Research Abstract for 2024. The award and abstract entitled, “Safety and Efficacy of Synchronous Ultrasound Parallel Beam Technology to Lift the Upper Lip and Improve Perioral Rhytids” were presented during the which took place from October 17th through the 20th in Orlando, Florida.

Kavita Darji, MD, the study’s author noted, “As a graduated ASDS accredited research fellow, I am incredibly grateful to have received this accolade from an esteemed panel of industry peers at ASDS. As people age, the production and density of elastin decreases, which can lead to wrinkles and skin laxity. The study’s interim analysis highlighted the fact that in just two treatments, 93% of patients’ appearance improved at the 1- and 3-month period. Moreover, the treatment effect remained in 58% of the subjects at six months after treatment. In the same way, an impressive 85% of subjects also noted a remarkable improvement in their own appearance at the 6-month period after the last treatment. The results truly place an industry spotlight on the effectiveness of Sofwave’s SUPERB™ ultrasound technology - a next-generation device to easily target the mid-dermis in order to maximize new collagen production and skin elasticity.”

Louis Scafuri, Sofwave CEO, noted, “We commend Dr. Darji for her efforts to further add to Sofwave’s clinical body of research. We believe that our treatments represent the future of non-invasive skin regeneration and the growth in the interest of our treatments and devices is an encouraging sign of market acceptance.”

Interim Analysis Results Highlighted in the Study

  • Patients’ results were measured in accordance with the Physician Global Aesthetic Improvement Scale (PGAIS).
  • Following the first treatment, 36% of the subjects had an improvement according to the study investigators assessments and in accordance with the PGAIS.
  • This rate increased to 93% at 1- and 3-month following the second treatment (at FU1 and FU2, respectively). The treatment effect remained at most of the subjects (58%) also six months after treatment (FU3).



The study remains ongoing.

The Drs. Alastair and Jean D. Carruthers Award is given annually and was designed by the ASDS Accreditation Work Group to stimulate interest and acknowledge cosmetic research contributions of Fellows of ASDS-accredited fellowship programs.

About Sofwave Medical

 has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), to improve the appearance of skin laxity on the upper arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The company’s Pure Impact™ module uses EMS technology and is cleared for muscle toning. Sofwave’s products provide physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: 

Investor Contact:

Brian Ritchie

LifeSci Advisors LLC

(212) 915-2578

A photo accompanying this announcement is available at



EN
22/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SOFWAVE MEDICAL LTD

 PRESS RELEASE

Sofwave to Participate in Jefferies Global Healthcare Conference

Sofwave to Participate in Jefferies Global Healthcare Conference SAN CLEMENTE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW),  an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Assaf Korner, Chief Financial Officer, will provide a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York from June 3-5, 2025. Jefferies Global Healthcare ConferencePresentation Format: Corporate overviewPresentat...

 PRESS RELEASE

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results an...

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights — First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3%— First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth— IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2025, for th...

 PRESS RELEASE

Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annua...

Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 Launch of the liftHD body applicator provides opportunity for next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance in order to achieve SUPERB results beyond the face Four abstract poster presentations highlighting clinical applications and results of Sofwave’s SUPERB™ non-invasive medical aesthetic technology will also be on exhibit SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ...

 PRESS RELEASE

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regu...

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region Japan represents third largest non-surgical medical aesthetic market in the world SAN CLEMENTE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave’s SUPERB™ Technology. Market appr...

 PRESS RELEASE

Sofwave to Participate in Upcoming Conferences

Sofwave to Participate in Upcoming Conferences SAN CLEMENTE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the following conferences: 24th Annual Needham Virtual Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, April 9, 2025Presentation Time: 9:30 a.m. ETWebcast: Wells Fargo 2025 Virtual Private MedTech...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch